Foundayo, a new daily pill for diabetes management and weight loss, is now available in UK pharmacies via private prescription. This oral treatment offers an alternative for patients who cannot use injectable weight-loss medications. The drug is intended for individuals with a BMI of 30 or above, or those with a BMI between 27 and 30 with weight-related conditions.
Pharmacists have raised concerns about counterfeit GLP-1 medications, as the ease of producing pills increases the risk of unlicensed products. Eli Lilly is working with health authorities to assess Foundayo for potential inclusion in the NHS, aiming to expand access to effective weight-loss treatments.
Watch for updates on NHS inclusion of Foundayo, as its potential rollout could reshape access to diabetes and weight-loss treatments. Stay alert for pharmacist guidance on avoiding counterfeit medications, especially as demand for oral options rises.